Ticagrelor-induced thrombotic thrombocytopenic purpura
2018
AbstractRationale:Ticagrelor, a new type of P2Y12 receptor antagonist, has been highly recommended to be used in acute coronary syndrome by the latest guideline, but its side effects are not well-known. We seek to illustrate a potential fatal condition, thrombotic thrombocytopenic purpura (TTP), cau
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI